Image

Study of VA Combined With HAAG Regimen in Newly Diagnosed Intermediate and High-risk AML Patients

Recruiting
18 - 65 years of age
Both
Phase 2

Powered by AI

Overview

The purpose of this study is to evaluate the efficacy and safety of VA combined with HAAG in the induction treatment of newly diagnosed acute myeloid leukemia.

Description

This is a single-center, single-arm, prospective clinical study in newly diagnosed intermediate and high-risk AML patients. The patients will receive venetoclax, azacitidine combined with HAAG regimen in the induction treatment.

Eligibility

Inclusion Criteria:

  1. Newly diagnosed intermediate and high-risk AML according to the WHO (2022) classification of acute myeloid leukemia (non-APL).
  2. Age 18-65.
  3. ECOG score: 0-2.
  4. No history of previous chemotherapy or target therapy.
  5. Serum total bilirubin <= 2 times the upper limit of normal (ULN), alanine aminotransferase (ALT) <= 1.5 times ULN, aspartate aminotransferase (AST) <=1.5 times ULN;
  6. Creatinine clearance rate >=30 mL/min;
  7. Serum lipase <= 1.5 times ULN, amylase <= 1.5 times ULN;
  8. Capable to understand and willing to participate in this study, signed the informed consent form.

Exclusion Criteria:

  1. AML transformed with chronic myelogenous leukemia.
  2. Acute promyelocytic leukemia (type M3).
  3. Patients with a second malignancy requiring treatment.
  4. Patients with uncontrolled active infection.
  5. Patients with left ventricular ejection fraction < 0.5 by echocardiography or grade III/IV cardiovascular dysfunction according to the New York Heart Association Classification.
  6. Patients with hepatic and renal inadequacy: total serum bilirubin >=2.0 mg/dl, AST >=3 times ULN, serum creatinine clearance (Ccr) <50 ml / min.
  7. Patients with arterial oxygen saturation (SpO 2) was <95%.
  8. Patients with HIV infection.
  9. Patients with active hepatitis B or hepatitis C infection.
  10. Patients with other commodities that the investigators considered not suitable for the enrollment.

Study details

Intermediate Risk Acute Myeloid Leukemia, High Risk Acute Myeloid Leukemia

NCT06394011

The First Affiliated Hospital of Soochow University

14 May 2024

Step 1 Get in touch with the nearest study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.